These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 3222450)
1. Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: preliminary evidences. Altamura C; Mauri M; Cavallaro R; Colacurcio F; Gorni A; Bareggi S Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(5):689-94. PubMed ID: 3222450 [TBL] [Abstract][Full Text] [Related]
2. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses]. Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M Encephale; 1995; 21(6):417-24. PubMed ID: 8674466 [TBL] [Abstract][Full Text] [Related]
3. Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels. Altamura CA; Colacurcio F; Mauri MC; Moro AR; De Novellis F Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):25-35. PubMed ID: 1967847 [TBL] [Abstract][Full Text] [Related]
4. Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia. Kelly MW; Perry PJ; Coryell WH; Miller DD; Arndt SV Psychopharmacology (Berl); 1990; 102(4):514-20. PubMed ID: 2096408 [TBL] [Abstract][Full Text] [Related]
5. Factors affecting the clinical response to haloperidol therapy in schizophrenia. Bareggi SR; Mauri M; Cavallaro R; Regazzetti MG; Moro AR Clin Neuropharmacol; 1990; 13 Suppl 1():S29-34. PubMed ID: 2379182 [TBL] [Abstract][Full Text] [Related]
6. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients. Ko GN; Korpi ER; Kirch DG J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607 [TBL] [Abstract][Full Text] [Related]
7. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol. Chang WH; Shieh YS; Liu HC; Jann MW; Chien CP Eur Neuropsychopharmacol; 1994 Jun; 4(2):119-26. PubMed ID: 7919941 [TBL] [Abstract][Full Text] [Related]
8. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects. Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612 [TBL] [Abstract][Full Text] [Related]
9. Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility. Santos JL; Ramos JA; Prieto P; Almoguera I; Vazquez C; Rubio ME; Cabranes JA Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):917-25. PubMed ID: 2813809 [TBL] [Abstract][Full Text] [Related]
10. Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis. Stevens A; Stevens I; Mahal A; Gaertner HJ Pharmacopsychiatry; 1992 Nov; 25(6):273-7. PubMed ID: 1494594 [TBL] [Abstract][Full Text] [Related]
11. Haloperidol plasma levels and dose optimization. Coryell W; Miller DD; Perry PJ Am J Psychiatry; 1998 Jan; 155(1):48-53. PubMed ID: 9433338 [TBL] [Abstract][Full Text] [Related]
14. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate]. Viala A; Aymard N; Leyris A; Caroli F Therapie; 1996; 51(1):19-25. PubMed ID: 8762216 [TBL] [Abstract][Full Text] [Related]
15. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report. Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368 [TBL] [Abstract][Full Text] [Related]
16. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia. Convit A; Volavka J; Czobor P; de Asis J; Evangelista C Am J Psychiatry; 1994 Jan; 151(1):49-56. PubMed ID: 8267134 [TBL] [Abstract][Full Text] [Related]
17. Correlation of clinical response (PANSS) and plasma levels of haloperidol and reduced haloperidol in schizophrenia. Leroux JM; Elia E; Jacquet M; Pommery J; Levron JC; Bouhours P; Erb F; Sechter D Prog Neuropsychopharmacol Biol Psychiatry; 1994 Mar; 18(2):347-53. PubMed ID: 8208983 [TBL] [Abstract][Full Text] [Related]
18. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays. Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566 [TBL] [Abstract][Full Text] [Related]
19. Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics. Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YF; Jann MW Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):105-12. PubMed ID: 8416597 [TBL] [Abstract][Full Text] [Related]
20. Megabore capillary gas-liquid chromatographic method with nitrogen-phosphorus selective detection for the assay of haloperidol and reduced haloperidol in serum: results of therapeutic drug-monitoring during acute therapy of eight schizophrenics. Ulrich S; Meyer FP; Neuhof S; Knorr W J Chromatogr B Biomed Appl; 1995 Jan; 663(2):289-96. PubMed ID: 7735476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]